deferiprone has been researched along with Cardiovascular Diseases in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| "Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months." | 1.43 | Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumfu, S | 1 |
| Chattipakorn, SC | 1 |
| Fucharoen, S | 1 |
| Chattipakorn, N | 1 |
| Origa, R | 1 |
| Bina, P | 1 |
| Agus, A | 1 |
| Crobu, G | 1 |
| Defraia, E | 1 |
| Dessì, C | 1 |
| Leoni, G | 1 |
| Muroni, PP | 1 |
| Galanello, R | 1 |
2 other studies available for deferiprone and Cardiovascular Diseases
| Article | Year |
|---|---|
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca | 2016 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |